(NXG) NexgenRX - Ratings and Ratios
Exchange: V •
Country: Canada •
Currency: CAD •
Type: Common Stock •
ISIN: CA65337X1042
Claims, Management, Administration, Programs, Services, Healthcare, Benefits
Description: NXG NexgenRX
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada., Web URL: https://www.nexgenrx.com
Additional Sources for NXG Stock
NXG Stock Overview
| Market Cap in USD | 19m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Managed Health Care |
| IPO / Inception |
NXG Stock Ratings
| Growth Rating | 34.3 |
| Fundamental | 37.1 |
| Dividend Rating | 39.3 |
| Rel. Strength | 44.9 |
| Analysts | - |
| Fair Price Momentum | 0.33 CAD |
| Fair Price DCF | 0.23 CAD |
NXG Dividends
| Dividend Yield 12m | 3.20% |
| Yield on Cost 5y | 5.56% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 97.5% |
| Payout Ratio | 200.0% |
NXG Growth Ratios
| Growth Correlation 3m | 28.1% |
| Growth Correlation 12m | 55.5% |
| Growth Correlation 5y | -5.3% |
| CAGR 5y | 15.28% |
| CAGR/Max DD 5y | 0.29 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | 26.47 |
| Beta | 0.714 |
| Volatility | 18.37% |
| Current Volume | 0k |
| Average Volume 20d | 0k |
What is the price of NXG shares?
As of July 06, 2025, the stock is trading at CAD 0.36 with a total of 0 shares traded.
Over the past week, the price has changed by +5.88%, over one month by +28.57%, over three months by +46.46% and over the past year by +38.25%.
As of July 06, 2025, the stock is trading at CAD 0.36 with a total of 0 shares traded.
Over the past week, the price has changed by +5.88%, over one month by +28.57%, over three months by +46.46% and over the past year by +38.25%.
Is NexgenRX a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, NexgenRX (V:NXG) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.07 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NXG is around 0.33 CAD . This means that NXG is currently overvalued and has a potential downside of -8.33%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, NexgenRX (V:NXG) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.07 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NXG is around 0.33 CAD . This means that NXG is currently overvalued and has a potential downside of -8.33%.
Is NXG a buy, sell or hold?
NexgenRX has no consensus analysts rating.
NexgenRX has no consensus analysts rating.
What are the forecasts for NXG share price target?
According to our own proprietary Forecast Model, NXG NexgenRX will be worth about 0.4 in July 2026. The stock is currently trading at 0.36. This means that the stock has a potential upside of +5.56%.
According to our own proprietary Forecast Model, NXG NexgenRX will be worth about 0.4 in July 2026. The stock is currently trading at 0.36. This means that the stock has a potential upside of +5.56%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.3 | 1080.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.4 | 5.6% |